Figure 3 Serum TT concentration 24 h pattern (with dispersion indices) under steady-state pharmacological conditions for the buccal, oral, subcutaneously injected, and transdermal patch PA-TRTs.
The horizontal axis of each graph shows the time in hours after the first dose of the day for those PA-TRTs administered more than once daily (A-C).
(A) Striant®, testosterone mucoadhesive buccal tablet (30 mg T/dose) inserted twice daily to the upper gum above the incisor tooth, on both sides of the mouth, as a 60 mg T daily dose (N =82). Actient Pharmaceuticals LLC.
[ATTACH=full]26664[/ATTACH]
Adapted from https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21543s002lbl.pdf. / last accessed May 2022.
(B) Jatenzo®, soft gel oral capsules ingested twice daily with meals as a total daily dose ranging between 158 and 396 mg testosterone undecanoate (N =166). Claus Therapeutics, Inc.
[ATTACH=full]26665[/ATTACH]
/ Adapted from https://www.accessdata.fda .gov/drugsatfda_docs/label/2019/206089s000lbl.pdf. / last accessed May 2022.
(C) Xyosted®, testosterone enanthate self-administered by subcutaneous injection to the abdominal region at weekly intervals as a daily dose of ≥75 mg (N =13). Antares Pharma, Inc.
[ATTACH=full]26666[/ATTACH]
/ Adapted from https://www.xyosted.com/PI.pdf. / last accessed May 2022.
(D) Androderm®, testosterone patch applied nightly (∼22:00 h) in a dose either of 2.5 mg T daily (one 2.5 mg T patch; N =29), 5 mg T daily (as two 2.5 mg patches; N =27), and 7.5 mg T daily (as three 2.5 mg patches; N =2). Watson Pharma, Inc. /
[ATTACH=full]26667[/ATTACH]
Adapted from https://www.accessdata .fda.gov/drugsatfda_docs/label/2011/020489s025lbl.pdf. / last accessed May 2022. Designated high and low normal limits (dashed lines) of TT for Androderm®, the PA-TRT that most closely approximates the circadian rhythm of healthy young males, are upper and lower circadian time-qualified 95% confidence limits of the normal blood TT concentration of young healthy men.
